Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  von Euw, Erika ^a   Atefi, Mohammad ^a   Attar, Narsis ^a   Chu, Connie ^a   Zachariah, Sybil ^a   Burgess, Barry L ^b   Mok, Stephen ^a   Ng, Charles ^a   Wong, Deborah J L ^a   Chmielowski, Bartosz ^a   Lichter, David I ^d   Koya, Richard C ^c   McCannel, Tara A ^b,c   Izmailova, Elena ^d   Ribas, Antoni ^a,c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e UCLA MEDICAL CENTER   (United States)

Author keywords

BRAF mutation; MAPK signaling; MEK inhibitor; Melanoma; Oncogenes

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; FLUORODEOXYGLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAK 733; TRACER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MUTANT; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MELANOMA; ONCOGENE; ONCOGENE N RAS; TUMOR CELL LINE; UVEA MELANOMA; WESTERN BLOTTING; WILD TYPE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE SIGNALING SYSTEM; MELANOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; PYRIMIDINONES; RADIOACTIVE TRACERS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 84859810061     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-22     Document Type: Article

References (31)

1. Padua RA, Barrass N, Currie GA. A novel transforming gene in a human malignant melanoma cell line. Nature 1984, 311:671-673. 10.1038/311671a0, 6090953.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
3. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147. 10.1056/NEJMoa050092, 16291983.
4. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602. 10.1038/nature07586, 2696133, 19078957.
5. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363:2191-2199. 10.1056/NEJMoa1000584, 3107972, 21083380.
6. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857. 10.1038/nature05661, 17314971.
7. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362. 10.1038/nature04304, 3306236, 16273091.
8. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599. 10.1038/nature09454, 2948082, 20823850.
9. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, Macconaill LE, Barretina JG, Kehoe SM, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. J Transl Med 2010, 8:39. 10.1186/1479-5876-8-39, 2876068, 20406486.
10. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010, 107:14903-14908. 10.1073/pnas.1008990107, 2930420, 20668238.
11. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819. 10.1056/NEJMoa1002011, 20818844.
12. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 21639808.
13. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714. 10.1056/NEJMoa1112302, 22356324.
14. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008, 68:664-673. 10.1158/0008-5472.CAN-07-2615, 18245465.
15. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008, 40:600-608. 10.1038/ng.115, 2410301, 18372904.
16. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009, 106:4519-4524. 10.1073/pnas.0900780106, 2649208, 19251651.
17. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, Pavey S, van der Velden P, Out C, Jager MJ, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005, 92:2032-2038. 10.1038/sj.bjc.6602598, 2361800, 15928660.
18. Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, Wittekind C, Wiedemann P, Tannapfel A. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Investig 2003, 83:1771-1776. 10.1097/01.LAB.0000101732.89463.29, 14691295.
19. Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, O'Connell SM, Scorah N, Shi L, Wallace MB, Zhou F. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett 2011, 21:1315-1319. 10.1016/j.bmcl.2011.01.071, 21310613.
20. O' Connell S, Tsuchiya S, Shi L, Fabrey R, Zhang L, Dong Q, Hori A, Vincent P. BRAF is not the only predictor of sensitivity in vitro and in vivo for TAK-733, a selective potent inhibitor of MEK1/2. Proc Am Assoc Canc Res 2010, Abstract #2523.
21. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009, 106:20411-20416. 10.1073/pnas.0905833106, 2777185, 19915144.
22. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011, 6:e28973. 10.1371/journal.pone.0028973, 3237573, 22194965.
23. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103. 10.1038/nature10868, 22281684.
24. Shi H, Kong X, Ribas A, Lo RS. Combinatorial Treatments That Overcome PDGFR{beta}-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition. Cancer Res 2011, 71:5067-5074. 10.1158/0008-5472.CAN-11-0140, 3149831, 21803746.
25. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012, 18:555-567.
26. Infante JR, Fecher LA, Nallapareddy S, Gordon MS, Flaherty KT, Cox DS, DeMarini DJ, Morris SR, Burris HA, Messersmith WA. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 2010, Abstract 2503.
27. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchokk GS. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010, 28:611s.
28. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999, 6:559-568. 10.1016/S1074-5521(99)80088-X, 10421767.
29. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366:207-215. 10.1056/NEJMoa1105358, 22256804.
30. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009, 4:e7887. 10.1371/journal.pone.0007887, 2774511, 19924296.
31. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A 2009, 106:12932-12937. 10.1073/pnas.0906606106, 2714280, 19625624.